体内：GDC-0077 (po) 在患者来源的PIK3CA-突变乳腺癌异种移植模型中以剂量依赖性方式导致肿瘤消退、细胞凋亡诱导和 pAKT、pPRAS40 和 pS6RP 减少<支持>[1]。参考文献：[1]. R Hong, Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast ...
参考文献: [1]. R Hong, Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. 2017 San Antonio Breast Cancer Symposium....
高血糖是与用pi3kα抑制剂的治疗相关的剂量限制性毒性(juricd等人(2013)proceedingsofthe104thannualmeetingoftheamericanassociationforcancerresearch;2013年4月6-10日;washington,dc.philadelphia(pa):aacr;cancerres2013b;73(8suppl):abstractnrlb-64)。用pi3k途径抑制剂的高血糖管理指南已建议将二甲双胍作为一线治疗...
hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: phase III INAVO120 primary analysis. Presented at: 2023 San Antonio Breast Cancer Symposium; San Antonio, Texas; December 5-9, 2023. Abstract GS03-13.
[1]. R Hong, Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. 2017 San Antonio Breast Cancer Symposium....
6、高血糖是与用pi3kα抑制剂的治疗相关的剂量限制性毒性(juric d等人(2013)proceedings of the 104th annual meeting of the american association forcancer research;2013年4月6-10日;washington,dc.philadelphia(pa):aacr;cancerres 2013b;73(8suppl):abstract nr lb-64)。用pi3k途径抑制剂的高血糖管理指南...
[1]. R Hong, Abstract PD4-14: GDC-0077 is a selective PI3Kalpha inhibitor that demonstrates robust efficacy in PIK3CA mutant breast cancer models as a single agent and in combination with standard of care therapies. 2017 San Antonio Breast Cancer Symposium. 详情:https://www.medchemexpress.cn...